A Randomized Trial Examining the Effectiveness of Switching From Olanzapine, Quetiapine, or Risperidone to Aripiprazole to Reduce Metabolic Risk: Comparison of Antipsychotics for Metabolic Problems (CAMP) by Stroup, T. Scott et al.
Comparison of Antipsychotics for Metabolic Problems (CAMP):
A randomized trial examining the effectiveness of switching
from olanzapine, quetiapine, or risperidone to aripiprazole to
reduce metabolic risk
T. Scott Stroup, MD, MPH1, Joseph P. McEvoy, MD2, Kimberly D. Ring, MPH3, Robert H.
Hamer, PhD3,4, Lisa M. LaVange, PhD3, Marvin S. Swartz, MD2, Robert A. Rosenheck, MD5,
Diana O. Perkins, MD, MPH4, Abraham M. Nussbaum, MD, MT6, and Jeffrey A. Lieberman,
MD1
1Columbia University College of Physicians and Surgeons
2Duke University Medical Center
3University of North Carolina School of Public Health
4University of North Carolina School of Medicine
5Yale University School of Medicine
6University of Colorado School of Medicine
Abstract
Objective—We conducted a multi-site, randomized controlled trial examining the strategy of
switching from olanzapine, quetiapine, or risperidone to aripiprazole to ameliorate metabolic risk
factors for cardiovascular disease.
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Method—Patients with schizophrenia or schizoaffective disorder with BMI ≥ 27 and non-HDL
cholesterol (non-HDL-C) ≥ 130 mg/dl on a stable dosage of olanzapine, quetiapine, or risperidone
were randomly assigned to stay on the current medication (n=106) or switch to aripiprazole
(n=109) for 24 weeks. All participants were enrolled in a behaviorally oriented diet and exercise
program. Raters were blinded to treatment assignment. The primary and key secondary outcomes
were non-HDL-C change and efficacy failure, respectively.
Results—The pre-specified primary analysis included 89 switchers and 98 stayers who had at
least one post-baseline non-HDL-C measurement. The least squares mean estimates of non-HDL-
C decreased more for the switch than the stay groups (−20.2 vs. −10.8 mg/dl). Switching was
associated with larger reductions in weight (2.9 kg) and a net reduction of serum triglycerides of
32.7 mg/dl. Twenty-two (20.6%) switchers and 18 (17.0%) stayers experienced protocol-defined
efficacy failure. Forty-seven (43.9%) switchers and 26 (24.5%) stayers discontinued the assigned
antipsychotic before 24 weeks.
Conclusion—Switching to aripiprazole led to improvement of non-HDL-C and other metabolic
parameters. Rates of efficacy failure were similar between groups, but switching to aripiprazole
was associated with a higher rate of treatment discontinuation. In the context of close clinical
monitoring, switching from an antipsychotic with high metabolic risk to one with lower risk to
improve metabolic parameters is an effective strategy.
Some commonly used antipsychotic medications (e.g., olanzapine, quetiapine, and
risperidone) are associated with increased rates of metabolic abnormalities that predispose
patients to cardiovascular disease (CVD) (1–7). Recent evidence has demonstrated that
individuals with severe mental disorders have substantially shortened life expectancy, with
cardiovascular diseases among the leading causes of premature mortality (8). Thus,
appropriate treatment strategies for patients who take antipsychotics and who also have
significant risk factors for CVD are needed. Among the methods for managing this risk in
patients treated with antipsychotic drugs, switching from drugs with a high liability for
producing metabolic side effects to an antipsychotic with a low liability is a commonly
chosen option, albeit with uncertain effectiveness. This is of particular interest for
individuals with schizophrenia or schizoaffective disorder who are clinically stable on an
antipsychotic medication that has a relatively high risk of metabolic side effects. The
possible benefits of switching to a medicine associated with fewer adverse metabolic effects
must be weighed against the potential risk of clinical instability associated with changing
treatment.
There are numerous modifiable risk factors for cardiovascular disease, including obesity,
dyslipidemias, hypertension, and impaired glucose metabolism (including insulin resistance
and diabetes mellitus). Recent attention has focused on non-HDL cholesterol (non-HDL-C),
which contains all known and potentially atherogenic lipid particles, and has been shown in
large cohort studies to be strongly associated with cardiovascular morbidity and mortality.
For example, the Lipid Research Clinics Program Follow-up Study, which followed a cohort
of 2,462 middle-aged men and women for an average of 19 years, found that non-HDL
cholesterol at study entry was a strong predictor of CVD mortality (9). An increase of 30
mg/dL of non-HDL-C was associated with a 19% increase in CVD mortality in men and a
15% increase in women. In the Bypass Angioplasty Revascularization Investigation (BARI),
in which 1514 patients with multi-vessel coronary artery disease were followed for 5 years,
non-HDL-C was strongly and independently associated with nonfatal myocardial infarction
and angina pectoris, with an increase of 10 mg/dL associated with a 5% increase in both of
these conditions (10).
We report the primary and key secondary efficacy and safety results of a 24-week,
randomized controlled clinical trial that examined the effectiveness of switching patients
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with schizophrenia or schizoaffective disorder from treatment with olanzapine, quetiapine,
or risperidone to treatment with aripiprazole as a strategy to reduce metabolic problems
associated with antipsychotic medications. We considered studying the switch to other
antipsychotics with favorable metabolic profiles, including ziprasidone and molindone (3, 6,
11–13), but chose aripiprazole because it was the newest option and we expected it would be
of most clinical interest when the study was completed.
We hypothesized that switching to aripiprazole would result in an improvement in metabolic
measures compared to staying on the current antipsychotic medication. We also sought to
determine if clinical destabilization due to switching from an antipsychotic that was working
well would accompany any metabolic benefits of switching to aripiprazole. The primary
efficacy outcome was the difference in non-HDL-C change from baseline between the two
treatment groups. The key secondary outcome was efficacy failure, defined in the protocol
as psychiatric hospitalization, a 25% increase in the total Positive and Negative Syndrome
Scale (PANSS)(14) score, or ratings of much worse or very much worse on the Clinical
Global Impression-Change Scale (15).
Methods
The Comparison of Antipsychotics for Metabolic Problems (CAMP) was a multi-site,
parallel-group, randomized controlled clinical trial. Participants were individuals with
schizophrenia or schizoaffective disorder who had achieved clinical stability on treatment
with olanzapine, quetiapine, or risperidone, and who were at increased risk for
cardiovascular disease as indicated by a body-mass index (BMI) ≥ 27 and a non-HDL-C
≥130 mg/dl (if non-HDL-C was 130 to 139, then LDL cholesterol was required to be ≥ 100
mg/dl). Patients were required to be on the qualifying drug for a minimum of three months
and without dosage adjustments or any other antipsychotic for one month prior to
enrollment. The reason that patients entered the study was a desire to improve their
metabolic risk profile. All participants provided written informed consent after study
procedures had been fully explained. The study was conducted at 27 clinical research
centers affiliated with the Schizophrenia Trials Network in the U.S.
Patients were randomly assigned on a 1:1 basis to switch to aripiprazole or to stay on their
current antipsychotic medication. Treatment assignment (stay versus switch) was stratified
by antipsychotic medication taken when entering the study (olanzapine, quetiapine, and
risperidone) and implemented centrally via a web-based system accessed by the clinical
centers. Individuals assigned to stay on their current antipsychotic treatment remained on the
pre-study dosage with adjustments only as clinically indicated. The allowed dosages were as
follows: olanzapine 5–20 mg daily, quetiapine 200–1200 mg daily, and risperidone 1–16 mg
daily. Patients assigned to switch to aripiprazole began taking aripiprazole 5 mg daily and
continued their previous antipsychotic medication and dose for one week. After one week
the dosage of aripiprazole was increased to 10 mg daily and the previous drug’s dosage was
reduced 25–50%. After two weeks dosage of aripiprazole could be increased to 15 mg daily
while the previous drug’s dosage was reduced 50–75% from the original dosage. After 3
weeks the available range for aripiprazole was 5–20 mg daily and the previous drug was
stopped. After 4 weeks the allowed dosage range for aripiprazole was 5–30 mg daily.
All participants received a manualized behavioral intervention, adapted from a group
treatment (16, 17), which was aimed at improving exercise and diet habits to reduce the risk
of cardiovascular disease. Patients returned to the clinic for weekly visits during the first
month of the treatment period and every four weeks after that. Laboratory assessments were
conducted every four weeks. The behavioral intervention was provided in person at all post-
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baseline study visits. After the first four weeks, study personnel made a telephone call to
reinforce the behavioral treatment lessons between each of the monthly visits.
Raters of symptoms (PANSS), global clinical status (CGI), and extrapyramidal side effects
(the Abnormal Involuntary Movement Scale (18), the Barnes Akathisia Scale (19), and the
Simpson-Angus Extrapyramidal Symptoms Scale (20)) were blinded to treatment
assignment. Participants and their physicians were aware of the medication assignment.
The addition of lithium, valproate, lipid lowering agents such as statins, or drugs prescribed
for weight loss was not allowed during the trial because of effects on the primary study
outcome. Individuals taking stable doses of lithium, valproate or lipid lowering medications
at the time of study entry could continue these treatments, but dose adjustments during the
treatment period were not allowed. Initiation or change in dose of one of these medicines
was considered a protocol violation. All other medications, except for non-study
antipsychotics, were allowed.
Statistical methods
The primary efficacy analysis was conducted on the efficacy evaluable population, defined
as all randomized patients receiving at least one dose of study medication and completing at
least one post-baseline efficacy assessment, and corresponded to a comparison between
randomization groups (stay versus switch) in change from baseline to 24 weeks in non-
HDL-C. Repeated measurements mixed effects linear models were fit for the primary
analysis and secondary analyses of continuous outcomes that appropriately accounted for the
correlation among repeated clinical assessments and randomly missing data (21). Models
included fixed effects for stratification (incoming medication), pooled clinical site, baseline
value, treatment, time (weeks in study), and time by treatment interactions. An unstructured
variance- covariance matrix was assumed, and least squares means at 24 weeks was the a
priori basis for the treatment comparisons. Outcome measurements obtained following a
prohibited change in dose or initiation of a disallowed medication were excluded from all
efficacy analyses, as specified a priori in the study protocol. The primary efficacy analysis
was repeated using all available measurements to assess the sensitivity of results.
Secondary analyses of efficacy failure and treatment discontinuation were based on the
intention-to-treat population (ITT), defined as all randomized patients receiving at least one
dose of study medication. Cochran-Mantel-Haenszel tests stratified by incoming medication
were used to compare treatment groups with respect to the proportion experiencing efficacy
failure and the proportion discontinuing treatment. Kaplan-Meier curves were generated for
time to efficacy failure and time to treatment discontinuation, and treatment group were
compared using log rank tests. Cox proportional hazards models were additionally fit to
compare time to event outcomes controlling for incoming medication and pooled clinical
site.
Results
The study was conducted between January 2007 and March 2010. Figure 1 demonstrates the
progress of patients screened and randomized. Of the 215 patients who were randomized,
109 were assigned to switch to aripiprazole and 106 to stay on the current antipsychotic.
Baseline demographic and clinical characteristics of all randomized patients are shown in
Table 1.
Two patients who were assigned to switch never took study drug and were therefore not
included in the ITT population. Eighteen (16.8%) of those in the switch group compared to 8
(7.5%) in the stay group stopped the protocol-specified treatment in the first four weeks,
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before completion of the time allowed for cross-titration to aripiprazole and before the first
follow-up laboratory tests were conducted, and were therefore excluded from the efficacy
evaluable population. Of these, 17 (15.9%) switchers and six (5.6%) stayers discontinued
the assigned antipsychotic and the remaining three (one switcher and two stayers) took
disallowed medications in the first month. The primary outcome and other metabolic
parameters were evaluated in 89 switchers and 98 stayers who completed at least one month
of study participation and thus had at least one post-baseline measurement of the primary
outcome on the assigned treatment.
At study entry the mean daily doses of the qualifying medications were olanzapine 18.5 mg,
quetiapine 502 mg, and risperidone 4.1 mg. Mean daily doses for patients during the study
were 16.9 mg of aripiprazole, 18.0 mg of olanzapine, 572.0 mg of quetiapine, and 4.1 mg of
risperidone.
Metabolic outcomes
For the primary outcome, change in non-HDL-C , the least squares means decreased more
for the switch than the stay groups (−20.2 vs. −10.8 mg/dl), with a difference of −9.4 mg/dl
(95% Confidence Interval −2.2,−16.5, p = 0.010). Switchers lost more weight than stayers
(−3.6 vs. −0.7 kg) with a difference of −2.9 kg (95% CI −1.6, −4.2, p < 0.001), and had a
larger BMI reduction of −1.07 units (p < 0.001). Triglycerides decreased for the switch
group and increased for the stay group (−25.7 vs. +7.0 mg/dl), yielding a difference of –32.7
mg/dl (95% CI −12.1, −53.4, p=0.002). As seen in Table 2, there were no differences
between the treatment groups in changes in HDL or LDL cholesterol. The trend favoring
switching compared to staying in reducing the inflammatory marker C-reactive protein was
not significant. Figure 2 demonstrates the time course of changes in non-HDL-C,
triglycerides, and weight. The benefit of switching on non-HDL-C and triglycerides was
almost completely realized after only one month, while the advantage of switching on
weight change accrued over the 24 weeks of the study. In our models, time and time by
treatment parameters were significant for weight change but not for non-HDL-C or
triglycerides. Mean (± standard deviation) weight change per month on study treatment was
−0.8±1.4 kg for switchers and −0.1± 1.0 kg for stayers.
On measures of glucose metabolism and insulin sensitivity, there was no difference between
switchers and stayers on fasting glucose, fasting insulin, or glycosolated hemoglobin. Two
hours following oral ingestion of 75 mg of glucose, there was no difference in glucose levels
but the 2-hour insulin level decreased more for those assigned to switch compared to those
assigned to stay (−31.1 vs. −6.8 mg/dl), with a difference of −24.2 mg/dl (p = 0.014).
Measures of clinical status
Twenty-two (20.6%) patients assigned to switch to aripiprazole and 18 (17.0%) assigned to
stay on the current antipsychotic experienced efficacy failure (p=0.4872). There was no
difference in time to efficacy failure (hazard ratio for switching 0.747; 95% CI 0.395–1.413,
p=0.3703). There were no differences between groups in psychopathology changes as
measured by the Positive and Negative Syndrome Scale (PANSS) total score (p=0.5180),
change in CGI-Severity score (p=0.8566), or change in the Medical Outcomes Survey-Short
Form 12 Item (SF-12)(22) mental health scores (p=0.9680). The SF-12 physical health score
worsened slightly for the stayers and improved for the switchers, yielding an advantage for
the switchers of 3.7 units (p=0.0105). On the IWQOL-lite, a validated measure of quality of
life related to weight (23), switchers improved more than stayers (−14.2 vs. −4.7 units,
p=0.0028).
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Eighteen (16.8%) of those assigned to switch to aripiprazole discontinued the protocol-
specified treatment before one month had elapsed, compared to eight (7.5%) of those
assigned to stay on the current medication. Overall, 51 (47.7%) switchers and 29 (27.4%)
stayers stopped the protocol-specified treatment (by stopping the assigned antipsychotic or
beginning a prohibited medication) before 24 weeks (p=0.0019). Participants in the switch
group discontinued the protocol-specified treatment (for any cause) earlier than those in the
stay group (hazard ratio 0.456; 95% CI 0.285–0.728, p = 0.0010). Forty-seven (43.9%)
switchers and 26 (24.5%) stayers stopped taking the assigned antipsychotic altogether before
24 weeks.
Adverse Effects
We systematically inquired about 20 adverse events commonly associated with
antipsychotic medications. Table 3 demonstrates the frequency at which participants rated
each of these side effects at a severity of “moderate” or “severe”. Considering the adverse
effects reported after baseline with differences of approximately 5% or more between the
stay or switch groups, insomnia was more common in the switch group but there was more
sleepiness, hypersomnia, nausea, dry mouth, increased appetite, and akinesia among the
stayers. Among the switchers, 18 patients (16.8%) experienced a total of 21 serious adverse
events (SAEs; including medically significant or life-threatening events, hospitalizations, or
extended hospitalizations), compared to 10 stayers (9.4%) who experienced 14 SAEs. One
stayer and no switchers discontinued treatment due to akathisia/activation. Eight switchers
(7.5%) and 5 stayers (4.7%) were hospitalized for psychiatric reasons. There were no deaths
in the study.
Sensitivity Analysis
A sensitivity analysis of the primary efficacy outcome (change in non-HDL-C) was
conducted using a modified ITT population of participants with at least one post-baseline
non-HDL measurement. A repeated measurements mixed effects linear model was fit using
all available measurements of non-HDL-C, regardless of disallowed medication usage or
early discontinuation of the prescribed antipsychotic, to predict the change at week 24. The
change remained greater among patients switching to aripiprazole than those remaining on
original medication but statistical significance was not achieved. The difference in least
squares means was 5.8 mg/dl (p= 0.104).
Discussion
The study was conducted at 27 research sites in the U.S. that were selected to include a
demographically diverse population to enhance generalizability of the results. Enrollment
criteria were designed to include a wide spectrum of individuals who might consider
switching medications due to metabolic problems, although those with minimal metabolic
problems and those with severe metabolic problems that needed immediate intervention
were excluded. Thus the results of this study might best be generalized to individuals with
chronic schizophrenia or schizoaffective disorder with moderate metabolic problems, for
whom a medication change or a lifestyle intervention focused on diet and exercise is an
appropriate first step.
In this study switching from olanzapine, quetiapine, or risperidone to aripiprazole was
effective in helping many patients to improve their lipid profiles (lower non-HDL-C and
lower triglycerides) and lose weight. The 9 mg/dl reduction of non-HDL-C is slightly less
than the 10 mg/dl difference significantly reduced cardiovascular morbidity in the BARI
study (10). The 1.1 unit reduction in BMI is above the 1 unit considered clinically
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significant by a panel of antipsychotic experts who created monitoring guidelines (24).
Because weight loss was continuing at the end of the study, it is possible that our results
underestimate the long-term benefit of switching on this secondary outcome. Because non-
HDL-C was the primary pre-designated outcome, results pertaining to non-HDL-C are
stronger evidence than those for secondary outcomes. These results are consistent with those
in a randomized controlled trial reported by Newcomer and colleagues that examined
switching from olanzapine to aripiprazole over 16 weeks (25). In that study, switchers had a
3.21 kg advantage in weight after 16 weeks, a reduction in triglycerides compared to an
increase for the stayers, and approximately a 15.6 mg/dl larger reduction in non-HDL-C.
Aripiprazole is one of several antipsychotics, including ziprasidone and molindone,
associated with a relatively low risk of metabolic problems. In studies, switching to
ziprasidone has been associated with significant improvement in metabolic parameters (12,
13). In addition, other available strategies to address metabolic problems in patients taking
antipsychotic medications include statins (i.e., HMG-coA reductase inhibitors) to reduce
LDL-cholesterol (LDL-C) and metformin to reduce weight. Statins tend to have their
greatest benefits on LDL and triglycerides rather than HDL or weight. The different statins
have variable effects on LDL-C but typically associated with reductions in LDL-C of 30–
60% (26). Short-term studies of metformin have shown that it is effective and well-tolerated
in promoting weight loss among individuals who have recently gained weight while taking
an antipsychotic (27), individuals experiencing a first-episode of psychosis (28), and even
individuals whose increased weight is not of recent onset (29).
Switching antipsychotics by beginning aripiprazole at a low dose and titrating upward while
slowly discontinuing the previous antipsychotic over one month was not associated with a
significant increase in efficacy failures as indicated by need for hospitalization or substantial
worsening of symptoms or global clinical status. However, a larger percentage of
individuals assigned to switch to aripiprazole relative to individuals staying on their original
antipsychotic discontinued the assigned treatment over the 24 weeks of the study. In some
cases the medication discontinuation was attributed to inadequate efficacy by the study
clinician but did not meet the study criteria for efficacy failure. The protocol, of course, was
designed to minimize risks for participants, and allowed study physicians to intervene to
prevent problems before they became severe. For example, when clinical worsening was
detected study physicians could intervene by discontinuing the protocol-specified treatment,
thus averting full-blown efficacy failure. We investigated this possibility by comparing the
PANSS scores of participants who met the protocol’s efficacy failure criteria to the PANSS
scores of participants whose treatment discontinuations were judged to be due to inadequate
efficacy but did not meet the efficacy failure criteria; the mean (± standard deviation)
PANSS scores of those who met efficacy failure criteria were higher (71.7±22.9 vs.
59.5±15.2). This suggests that careful clinical monitoring following a medication switch,
accompanied by appropriate clinical intervention when poor efficacy is detected (e.g.,
stopping the new antipsychotic and restarting the previous one) can reduce the risk of severe
symptom exacerbations and need for hospitalization.
Because the goal of the study was to evaluate the effect of switching antipsychotic
medications on metabolic parameters, some common medication changes that were known
to affect these parameters were not allowed. For those few patients who took the proscribed
medications but continued the assigned antipsychotic, we only used measurements taken
before the disallowed change occurred in the primary analyses. Seven such deviations from
“protocol-specified” treatment occurred; four were in the switch group and three in the stay
group. In addition, some patients contributed data after they had stopped taking the assigned
antipsychotic. Results from the sensitivity analyses conducted to assess the impact of these
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exclusions and early dropouts for other reasons showed that the numerical advantage of
switching remained, although statistical significance was not achieved.
This report is focused on the primary comparison of staying on current medication or
switching. Secondary analyses examining the effects for each of the three allowed
antipsychotics at study entry are provided in supplementary tables. These secondary
analyses provide only suggestive information about the impact of switching from these
drugs.
Open-label treatment is a limitation of this study, particularly for outcomes not measured in
the laboratory but instead subject to clinical judgment. For example, a belief that olanzapine
has superior efficacy could have contributed to the early discontinuations among those who
entered the study taking olanzapine but were assigned to switch to aripiprazole
(Supplemental Table 3). The excess of early treatment discontinuations in the olanzapine
group suggests that switching from olanzapine was either more difficult than switching from
the other drugs or, perhaps, resulted from an expectation bias that this change would be the
most difficult.
In conclusion, switching from a medication associated with substantial risk of metabolic
problems to one with a lower risk of these problems is a reasonable clinical option if careful
cross-titration and close monitoring is possible. Careful clinical monitoring during and after
a switch is necessary, and the diligence of clinicians is likely a principal reason that
switchers did not experience a higher rate of efficacy failures than those who stayed on their
original antipsychotic. If switching medications is unsuccessful, other approaches to reduce
some of the risk factors for cardiovascular disease are available, including adding metformin
or a statin. The switch in medications was effective in the presence of a behavioral
intervention focused on improving diet and exercise habits, which had benefits even in the
comparison group that did not change medications.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Values are from efficacy evaluable population (n=187), and least squares means from the
mixed model are presented. Change from baseline was the outcome variable, and treatment,
week, baseline value, incoming medication, treatment by week interaction were covariates
in the mixed model. P-value for NonHDL change is 0.0102, p-value for weight change is <.
0001, and p-value for triglycerides change is 0.0020.
Kaplan-Meier curves on intent-to-treat population (n=215). Logrank test p-value is 0.2993
for time to efficacy failure in days and 0.0021 for time to all-cause treatment discontinuation
in days.
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